Analysis of social psychology and contact the Mainland news of Taiwan audience

自2008年以来，随着ECFA的签订、两岸三通的实现、大陆民众赴台个人游的开启，两岸在经济合作和人员往来中有了突飞猛进的发展，两岸关系大幅改善，但与此同时，政治、军事、文化、新闻等领域互动相对滞后的“短板”日益彰显，两岸双方如何巩固互信、累积共识、创造条件、破解难题，已经越来越迫切。两岸在制定政策时需要建立在具有相当共识的主流社会舆论基础上，才能推动双方进一步的交流与互信。对于大陆方面来说，有必要深入地展开对台湾地区舆情动向的研究，尤其是不能忽略对台湾“民意”的载体——受众这一群体的研究。 本文通过分析台湾受众的社会心理和媒介接触情况，来探寻建立两岸民意的沟通与共融之路径。研究发现，在独特的...Since 2008, with the signing of ECFA, the realization of “Three Links” and people from the Mainland to Taiwan as individual tourists, the relationship between the Mainland and Taiwan has made a rapid progress in the development of economic cooperation and people-to-people exchanges. However, the field of politics, military, culture and news interaction has lagged far behind. For the Mainland and T...学位：文学硕士院系专业：新闻传播学院_新闻学学号：1052010115292

热线追踪：这些事解决了吗？

厦门大学《凌云报》第56期第一版凌云热线作为校园生活的一扇窗口，“凌云热线”为学校和学生提供了一个双向交流的平台。在过去的一年中，“凌云热线”关注过餐厅秩序、饮食安全、出入管理、流浪猫狗等大家普遍反映的问题，也得到了相关部门的积极回应。在年末之时，“凌云热线”特推出“热线追踪”，回顾一下那些曾经困扰我们的问题，它们是否得到了解决？厦门大学研究生

新闻网站重大突发事件报道的框架分析——以人民网与凤凰网对“7·23动车事故”报道为例

本文借助新闻框架理论,运用内容分析和比较分析的方法,考察人民网和凤凰网对重大突发事件在新闻呈现上的差异及原因。通过分析发现两者的异同:在新闻材料选择上,人民网注重原创,突出权威性,凤凰网则更加多元化;在新闻材料建构上,人民网主要关注政府部门的反应与行动,而凤凰网则倾向于民事视角,但两者在报道框架上却出现一致

人民币汇率的前世今生与未来——经济学院副院长朱孟楠作客“院长论坛”

厦门大学《凌云报》第55期第二版后金融危机时代，全球货币战争烽烟四起，而随着中国对外开放向深度和广度扩展，人民币汇率变动、人民币汇率的市场化改革和人民币国际化等问题日益凸显，成为全世界热议的话题，也引起了校园里众多学子的关注。11月19日晚上，校研究生会在图书馆五楼南强学术报告厅举办第三十四场“院长论坛”。厦门大学经济学院副院长、金融学教授、博士生导师朱孟楠教授亲临现场，解密人民币汇率的前世今生与未来的全球博弈。厦门大学研究生

读好书，做好人，健康安全，全面发展——财政学泰斗邓子基寄语广大研究生

厦门大学《凌云报》第二版学术观察在厦门大学，有这样一位年近九旬的老教授，他喜欢把学生带到自己的书房，一起探讨学术问题，顺便让弟子们尝尝老伴最拿手的热汤面。他的身影每每出现在厦门大学校级典礼或会议上，都会引起学生的欢呼。有人称他为 “大师”、“泰斗”， 因为他是新中国财政学界的一代宗师。可是他说：“我不是大师，是老师。我不是泰斗，是‘老兵’。” 他最亲近的学生则称他为“邓爷爷”。 　　他就是八十八岁的中国财政学泰斗、厦门大学资深教授、博导邓子基先生。2010年11月5日，邓子基先生作客厦门大学第八期“名师下午茶”，在悠扬的古琴曲与怡人的茶香中，饶有兴致地与同学们分享了自己的人生故事与为学之道。厦门大学研究生

2010年，我们关注的那些事儿

厦门大学《凌云报》第56期第一版特别策划不知不觉，2010年就要离我们远去了。在这一年中，我们为世界杯和世博会欢呼过，为玉树和舟曲痛哭过，为李刚和3Q大战愤怒过，也为物价的上涨以及未来的前途纠结迷茫过……也许，这些喜怒哀乐已经随着时间渐渐变淡，那么就让我们打开记忆，一起回味这一年来曾经关注的那些事儿。厦门大学研究生

厦大师生聚焦学术规范

厦门大学《凌云报》第二版学术观察2010年8月29日，以“学术界打假斗士”而闻名的方舟子在北京住所附近遭遇伏击。此案后被证实与“肖氏反射弧”技术发明人肖传国因方舟子的举报未能入选中国科学院院士一事有关。这一因学术打假而导致的恶性事件，令学术不端行为再次成为公众关注的焦点。从浙大“贺海波论文造假事件”到《晶体学报》E分卷撤销井冈山大学90余篇论文，从东北财经大学“史上最牛硕士论文抄袭事件”到上海大学博导陈湛匀论文抄袭事件……仅在2009年，媒体曝光的学术不端事件就有近十起。2010年，叱吒商界多年的唐骏被方舟子质疑“学历造假”，在学术界享有盛誉的学者汪晖、朱学勤也被指在学术规范方面存在疏漏。而在中科协2009年公布的《第二次全国科技工作者状况调查报告》中，超过55.5%的科技工作者表示，确切知道自己周围的研究者有过至少一种学术不端行为。厦门大学研究生

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements